Baird Financial Group Inc. reduced its holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 65.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,005 shares of the biotechnology company’s stock after selling 5,683 shares during the period. Baird Financial Group Inc.’s holdings in Sarepta Therapeutics were worth $223,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. BB&T Securities LLC increased its position in Sarepta Therapeutics by 40.0% in the 1st quarter. BB&T Securities LLC now owns 7,995 shares of the biotechnology company’s stock worth $592,000 after buying an additional 2,286 shares during the period. Principal Financial Group Inc. increased its position in Sarepta Therapeutics by 2.7% in the 1st quarter. Principal Financial Group Inc. now owns 19,946 shares of the biotechnology company’s stock worth $1,478,000 after buying an additional 530 shares during the period. Symphony Asset Management LLC bought a new position in Sarepta Therapeutics in the 1st quarter worth approximately $266,000. Sei Investments Co. increased its position in Sarepta Therapeutics by 41.3% in the 1st quarter. Sei Investments Co. now owns 46,506 shares of the biotechnology company’s stock worth $3,446,000 after buying an additional 13,589 shares during the period. Finally, BNP Paribas Arbitrage SA increased its position in Sarepta Therapeutics by 12.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 17,582 shares of the biotechnology company’s stock worth $1,303,000 after buying an additional 1,907 shares during the period. 86.28% of the stock is currently owned by institutional investors.
Shares of SRPT stock opened at $137.74 on Tuesday. The company has a current ratio of 13.37, a quick ratio of 12.28 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $9.20 billion, a P/E ratio of -83.99 and a beta of 1.35. Sarepta Therapeutics Inc has a one year low of $32.36 and a one year high of $176.50.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.23). The company had revenue of $64.60 million during the quarter, compared to analyst estimates of $65.31 million. Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. Sarepta Therapeutics’s quarterly revenue was up 295.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.57) EPS. research analysts expect that Sarepta Therapeutics Inc will post -1.98 earnings per share for the current fiscal year.
SRPT has been the topic of several recent analyst reports. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. Barclays raised Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $55.00 to $107.00 in a research report on Friday, May 11th. ValuEngine raised Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Morgan Stanley boosted their price objective on Sarepta Therapeutics from $63.00 to $64.00 and gave the company an “overweight” rating in a research report on Tuesday, March 6th. Finally, William Blair restated a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, June 19th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $135.31.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.